What we do
The Roswell Park Comprehensive Cancer Center Data Bank and BioRepository (DBBR) shared resource prospectively collects and provides de-identified biospecimens and associated epidemiological and clinical data to investigators with Institutional Review Board (IRB) approved protocols. Newly diagnosed patients are asked to consent to collection of blood tubes, completion of a risk factor questionnaire and permission to link their samples to clinical data. DBBR samples and data can also be paired with tumor tissue from the Pathology Network Shared Resource and clinical data abstraction from the Biomedical Research Informatics Shared Resource.
Additionally, non-patients, family members and friends of patients, and community members with no personal history of cancer are asked to participate in the DBBR as healthy volunteers.
We strive to provide specimens that are rigorously collected, processed and stored so the integrity of potential analytes will be consistent across all patients and controls. Tubes are drawn and sent to the DBBR laboratory through the pneumatic tube system at Roswell Park for processing into serum, plasma, buffy coat, peripheral blood mononuclear cells (PBMC) and DNA.
With expertise in epidemiology, biospecimen science and study methods and design, including participant recruitment, data collection and management to support analysis, we work closely with investigators to hone their research concepts and identify the best available biospecimen and data sources to support their research needs. The DBBR carefully gathers investigators’ requirements and provides detailed biospecimen inventory reports for banked sample and data inquiries, options and strategies for prospective procurement of samples and data, and time and cost proposals for new grants and funded studies.
- -80C freezers
- Liquid nitrogen tanks
- Desiccators for paraffin embedded tissue storage
- Tutela wireless temperature monitoring system
- Rees wireless temperature monitoring system
- Perkin Elmer – Janus liquid handler
- Autogen XTRACT 16+ nucleic acid extractor
- Autogen - XTRACT 16+® DNA extractor
- Molecular Devices – Spectramax Gemini XS plate reader (Fluorescence)
- Molecular Devices – Spectramax 384 plus plate reader (UV/VIS)
- Invitrogen by Life technologies Qubit 2.0 fluorometer
- BioMicroLab – XL20 tube sorter
- Thermo Scientific – NanoDrop 2000 Spectrophotometer
- Thermofisher – Qubit Fluorometer
Services and fees
- Provision of serum, plasma, red blood cells, DNA, PBMC and buffy coat, linked with clinical and risk factor data
- Biospecimen inventory evaluation and study feasibility assessment
- Incorporation of Data Bank and BioRepository (DBBR) services in grants, protocols and subsequent publications
- Detailed tracking of investigator service history
- Linking and de-identifying data and study data file storage
- Creating derived variables and preparation of analysis-ready data sets
- Investigator study specific collections and serial draws
- Microbiome collections – stool, swab
Project pricing will vary based on nature of request. Please contact Annmarie Nowak, DBBR Coordinator and Director, at 716-845-8295 or Annmarie.Nowak@RoswellPark.org for a project specific cost estimate.
How to request samples and data
1. Feasibility discussion
At the time of initial inquiry, investigators are asked to meet with or arrange a telephone call with DBBR Operations Director Annmarie Nowak to assess:
- The availability of appropriate banked biospecimens and data to fulfill the study request and/or determination of the need and logistics of additional (study-specific) collection
- Anticipated time frame for the research
- Service cost estimate and funding source for the research
2. Have an IRB-approved protocol
(Non-Human Subjects Research form, if Roswell Park investigator). All data and samples provided by the DBBR are de-identified prior to release for use in research. The DBBR maintains the link between participants and their samples and data. Investigators never receive any information that would allow them to identify donors.
3. Obtain approval for request from the appropriate Disease Site Research Group (DSRG) if required
- Requests for finite patient material including serum, plasma, red blood cells and buffy coat require DSRG pre-approval.
- Requests for <=2 ug of DNA per subject do not require DSRG pre-approval.
- Requests for healthy control specimens do not require DSRG pre-approval.
Cancer Center Support Grant (CCSG) Program members with peer-reviewed funding are given top priority for requests, followed by Roswell Park investigators with newly developing programs, then external academic investigators with federal funding and finally commercial investigators. Fees for cost recovery are tiered for these different groups of investigators.
At the time of consent, each participant (patient or non-patient/control) is asked to complete a self-administered epidemiological questionnaire and return it via mail. The questionnaire contains over 1,100 items covering:
- Demographics and background
- Personal and family history of cancer
- Medical and cancer screening histories
- Women’s and men’s health issues
- Lifestyle (smoking, diet, physical activity, alcohol)
- Supplement and medication use
The questionnaire data dictionary and codebooks are available to investigators for research planning and analysis.
The DBBR maintains data handling procedures to maximize data integrity and quality and to sustain a minimum of a 75% response rate for the questionnaire:
- Questionnaires are scannable, minimizing the potential for data entry errors
- Patient portal access to electronic version
- Customized software is used for error checking
- Five-point follow up schedule used for missing surveys
- Participants are re-contacted for inconsistencies
Each sample collected from patients is annotated relative to the sample collection date, including:
- Diagnosis status (new, benign, follow up, recurrent); sample treatment status (pre-surgical, post-adjuvant therapy, etc.); personal history status (no prior history, prior history of same cancer, prior history of other cancer, prior history of multiple cancers) and personal history detail.
- Diagnosis date, laterality, histology, behavior, grade, tumor size, clinical and pathological stage, distant sites, tumor markers, surgery date and recurrence (as of the sample collection date). Linked to Roswell Park Cancer Registry.
- As needed, capture or link to extended clinical data including comorbidities, extended treatment history and medications at the time of sample collection, upon request.
All data (and samples) are provided to investigators de-identified only. Participant names and other protected health information are never distributed to scientists.
Recruitment and procurement
The focus of the DBBR is to collect blood samples from newly diagnosed patients prior to surgery or cytotoxic treatment. Patients who are post-treatment also are asked to participate based on identified future research needs.
The DBBR recruitment staff work with outpatient clinical staff to identify and get consent from patients and coordinate sample collection for the bank. Blood samples are collected alongside existing clinical laboratory orders and drawn by the phlebotomy service at Roswell Park. Family members and friends accompanying patients, as well as other visitors to Roswell Park, are also asked to donate samples as controls.
Control samples follow the same sample procurement and processing procedures as patient samples. Every participant is asked to donate 30 mL of blood; one 10-mL non-heparinized red top tube (for serum); one 10-mL EDTA lavender top tube for plasma and buffy coat; and a second 10-mL EDTA lavender top tube (whole blood for DNA).
For specific studies or groups 3 additional Heparin tubes are collected for Peripheral Blood Mononuclear Cell (PMBC) preparation. The phlebotomist prints sample barcode labels for the blood collection tubes using the Roswell Park laboratory management system. This procedure produces an alert signaling the pending arrival of specimens for processing in the biorepository processing laboratory. Samples are sent from phlebotomy to the sample processing laboratory via pneumatic tube delivery system.
Sample processing and storage
The standard time from collection to freeze for DBBR blood samples is one hour. Specimens are centrifuged and the supernatant is aliquoted into 2D barcoded Matrix tubes or cryovials. Aliquots include serum, plasma and buffy coat (0.5 mL each) which are stored in a liquid nitrogen vapor. In addition, whole blood is aliquoted in 2 ml barcoded cryovials and stored at -80oC.
For specific studies and / or populations, blood is processed with density gradient separation techniques using SepMate Tubes (Stem Cell Inc). These cells are aliquoted into 2D barcoded matrix tubes and slow frozen before transferring to liquid nitrogen vapor for long term storage.
Genomic DNA is readily available from extracted blood using an Autogen XTRACT 16+ nucleic extractor which allows rapid extraction from up to 48 samples per day, a Qubit fluorometer from Thermofisher that facilitates accurate quantification and evaluation of double stranded DNA and a Janus liquid handling system from Perkin Elmer Life Sciences which is used to automate distribution.
Location & hoursRoswell Park Comprehensive Cancer Center
Data Bank and BioRepository Shared Resource
Carlton House, Room 350
Elm and Carlton Streets
Buffalo, New York 14263
DBBR Recruitment Service: Monday – Friday, 7 a.m. – 5:30 p.m.
Laboratory Service: Monday – Friday, 6 a.m. – 6 p.m.
Data Service: Monday – Friday ,7 a.m. – 5 p.m.
This shared resource is funded by NCI P30CA16056. Publications should cite the core grant in the acknowledgment section, if publications use data generated by the shared resource. Two copies of the publication acknowledging the core grant should also be submitted to the facility at Elm & Carlton Streets, Buffalo, NY 14263.
The Data Bank and BioRepository (DBBR) is a comprehensive data and sample bank, with biospecimens, epidemiologic and clinical information for investigators conducting translational research related to cancer prevention, etiology, detection and treatment. Collection of specimens and data from participants is ongoing for use in future research studies.
Meet our team
Roswell Park Staff may reach DBBR Clinical Research Associates for recruitment issues by paging "DBBR" from inside the hospital. Recruitment staff may also be reached for questionnaire issues by telephone at 716-845-7774 or by email at DBBR@RoswellPark.org.
- Ademuyiwa FO, Bshara W, Attwood K, Morrison C, Edge SB, Ambrosone CB, O'Connor TL, Levine EG, Miliotto A, Ritter E, Ritter G, Gnjatic S, Odunsi K. NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer. PLoS One. 2012; 7(6):e38783. PMCID: PMC3386262
- Choi JY, James SR, Link PA, McCann SE, Hong CC, Davis W, Nesline MK, Ambrosone CB, Karpf AR.Association between global DNA hypomethylation in leukocytes and risk of breast cancer.Carcinogenesis. 2009 Nov;30(11):1889-97. PMCID: PMC2783000
- Erwin DO, Moysich K, Kiviniemi MT, Saad-Harfouche FG, Davis W, Clark-Hargrave N, Ciupak GL, Ambrosone CB, Walker C. Community-based partnership to identify keys to biospecimen research participation. J Cancer Educ. 2013 Mar;28(1):43-51. doi: 10.1007/s13187-012-0421-5
- Fakih MG, Trump DL, Johnson CS, Tian L, Muindi J, Sunga AY.Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer.Int J Colorectal Dis. 2009 Feb;24(2):219-24. Epub 2008 Oct 2. PMCID: PMC2715947
- Garcia E, Andrews C, Hua J, Kim HL, Sukumaran DK, Szyperski T, Odunsi K.Diagnosis of early stage ovarian cancer by 1H NMR metabonomics of serum explored by use of a microflow NMR probe.J Proteome Res. 2011 Apr 1;10(4):1765-71. Epub 2011 Feb 22. PMCID: PMC3074977
- Haiman CA, Chen GK, Vachon CM, Canzian F, Dunning A, Millikan RC, Wang X, Ademuyiwa F, Ahmed S, Ambrosone CB, Baglietto L, Balleine R, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Blot WJ, Brauch H, Buring JE, Carey LA, Carpenter JE, Chang-Claude J, Chanock SJ, Chasman DI, Clarke CL, Cox A, Cross SS, Deming SL, Diasio RB, Dimopoulos AM, Driver WR, Dünnebier T, Durcan L, Eccles D, Edlund CK, Ekici AB, Fasching PA, Feigelson HS, Flesch-Janys D, Fostira F, Försti A, Fountzilas G, Gerty SM; Gene Environment Interaction and Breast Cancer in Germany (GENICA) Consortium, Giles GG, Godwin AK, Goodfellow P, Graham N, Greco D, Hamann U, Hankinson SE, Hartmann A, Hein R, Heinz J, Holbrook A, Hoover RN, Hu JJ, Hunter DJ, Ingles SA, Irwanto A, Ivanovich J, John EM, Johnson N, Jukkola-Vuorinen A, Kaaks R, Ko YD, Kolonel LN, Konstantopoulou I, Kosma VM, Kulkarni S, Lambrechts D, Lee AM, Marchand LL, Lesnick T, Liu J, Lindstrom S, Mannermaa A, Margolin S, Martin NG, Miron P, Montgomery GW, Nevanlinna H, Nickels S, Nyante S, Olswold C, Palmer J, Pathak H, Pectasides D, Perou CM, Peto J, Pharoah PD, Pooler LC, Press MF, Pylkäs K, Rebbeck TR, Rodriguez-Gil JL, Rosenberg L, Ross E, Rüdiger T, Silva Idos S, Sawyer E, Schmidt MK, Schulz-Wendtland R, Schumacher F, Severi G, Sheng X, Signorello LB, Sinn HP, Stevens KN, Southey MC, Tapper WJ, Tomlinson I, Hogervorst FB, Wauters E, Weaver J, Wildiers H, Winqvist R, Van Den Berg D, Wan P, Xia LY, Yannoukakos D, Zheng W, Ziegler RG, Siddiq A, Slager SL, Stram DO, Easton D, Kraft P, Henderson BE, Couch FJ. A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011 Oct 30;43(12):1210-4. doi: 10.1038/ng.985
- Hampras SS, Nesline M, Wallace PK, Odunsi K, Furlani N, Davis W, Moysich KB. Predictors of immunosuppressive regulatory T lymphocytes in healthy women. J Cancer Epidemiol. 2012; 2012:191090. Epub 2012 Aug 26. PMCID: PMC3433139
- Hong CC, Yao S, McCann SE, Dolnick RY, Wallace PK, Gong Z, Quan L, Lee KP, Evans SS, Repasky EA, Edge SB, Ambrosone CB. Pretreatment levels of circulating Th1 and Th2 cytokines, and their ratios, are associated with ER-negative and triple negative breast cancers. Breast Cancer Res Treat. 2013 Jun;139(2):477-88. doi: 10.1007/s10549-013-2549-3. Epub 2013 Apr 30.
- Kiviniemi MT, Saad-Harfouche FG, Ciupak GL, Davis W, Moysich K, Hargrave NC, Ambrosone CB, Walker C, Erwin DO. Pilot intervention outcomes of an educational program for biospecimen research participation. J Cancer Educ. 2013 Mar;28(1):52-9. doi: 10.1007/s13187-012-0434-0
- Kulkarni S, Augoff K, Rivera L, McCue B, Khoury T, Groman A, Zhang L, Tian L, Sossey-Alaoui K. Increased expression levels of WAVE3 are associated with the progression and metastasis of triple negative breast cancer .PLoS One. 2012; 7(8):e42895. doi: 10.1371/journal.pone.0042895. Epub 2012 Aug 27. PMCID: PMC3428347
- McCann SE, Hootman KC, Weaver AM, Thompson LU, Morrison C, Hwang H, Edge SB, Ambrosone CB, Horvath PJ, Kulkarni SA.Dietary intakes of total and specific lignans are associated with clinical breast tumor characteristics.J Nutr. 2012 Jan;142(1):91-8. PMCID: PMC3237232
- Morrison, C, Gaudioso, C, Bshara, W. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours.Nature. 2012 Oct 4; 490(7418):61-70. doi: 10.1038/nature11412. Epub 2012 Sep 23. PMCID: PMC3465532
- Puthillath A, Trump DL, Andrews C, Bir A, Romano K, Wisniewski M, Fakih MG. Serological immune responses to influenza vaccine in patients with colorectal cancer. Cancer Chemother Pharmacol. 2011 Jan;67(1):111-5. doi: 10.1007/s00280-010-1292-2. Epub 2010 Mar 5
- Roberts MR, Hong CC, Edge SB, Yao S, Bshara W, Higgins MJ, Freudenheim JL, Ambrosone CB. Case-only analyses of the associations between polymorphisms in the metastasis-modifying genes BRMS1 and SIPA1 and breast tumor characteristics, lymph node metastasis, and survival.Breast Cancer Res Treat. 2013 Jun;139(3):873-85. doi: 10.1007/s10549-013-2601-3. Epub 2013 Jun 16.
- Rodriguez EM, Torres ET, Erwin DO. Awareness and interest in biospecimen donation for cancer research: views from gatekeepers and prospective participants in the Latino community. J Community Genet. 2013 Oct; 4(4):461-8. PMCID: PMC3773314
- Siddiq A, Couch FJ, Chen GK, Lindström S, Eccles D, Millikan RC, Michailidou K, Stram DO, Beckmann L, Rhie SK, Ambrosone CB, Aittomäki K, Amiano P, Apicella C; Australian Breast Cancer Tissue Bank Investigators, Baglietto L, Bandera EV, Beckmann MW, Berg CD, Bernstein L, Blomqvist C, Brauch H, Brinton L, Bui QM, Buring JE, Buys SS, Campa D, Carpenter JE, Chasman DI, Chang-Claude J, Chen C, Clavel-Chapelon F, Cox A, Cross SS, Czene K, Deming SL, Diasio RB, Diver WR, Dunning AM, Durcan L, Ekici AB, Fasching PA; Familial Breast Cancer Study, Feigelson HS, Fejerman L, Figueroa JD, Fletcher O, Flesch-Janys D, Gaudet MM; GENICA Consortium, Gerty SM, Rodriguez-Gil JL, Giles GG, van Gils CH, Godwin AK, Graham N, Greco D, Hall P, Hankinson SE, Hartmann A, Hein R, Heinz J, Hoover RN, Hopper JL, Hu JJ, Huntsman S, Ingles SA, Irwanto A, Isaacs C, Jacobs KB, John EM, Justenhoven C, Kaaks R, Kolonel LN, Coetzee GA, Lathrop M, Le Marchand L, Lee AM, Lee IM, Lesnick T, Lichtner P, Liu J, Lund E, Makalic E, Martin NG, McLean CA, Meijers-Heijboer H, Meindl A, Miron P, Monroe KR, Montgomery GW, Müller-Myhsok B, Nickels S, Nyante SJ, Olswold C, Overvad K, Palli D, Park DJ, Palmer JR, Pathak H, Peto J, Pharoah P, Rahman N, Rivadeneira F, Schmidt DF, Schmutzler RK, Slager S, Southey MC, Stevens KN, Sinn HP, Press MF, Ross E, Riboli E, Ridker PM, Schumacher FR, Severi G, Dos Santos Silva I, Stone J, Sund M, Tapper WJ, Thun MJ, Travis RC, Turnbull C, Uitterlinden AG, Waisfisz Q, Wang X, Wang Z, Weaver J, Schulz-Wendtland R, Wilkens LR, Van Den Berg D, Zheng W, Ziegler RG, Ziv E, Nevanlinna H, Easton DF, Hunter DJ, Henderson BE, Chanock SJ, Garcia-Closas M, Kraft P, Haiman CA, Vachon CM. A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet. 2012 Dec 15;21(24):5373-84. doi: 10.1093/hmg/dds381. Epub 2012 Sep 13.
- Stevens KN, Fredericksen Z, Vachon CM, Wang X, Margolin S, Lindblom A, Nevanlinna H, Greco D, Aittomäki K, Blomqvist C, Chang-Claude J, Vrieling A, Flesch-Janys D, Sinn HP, Wang-Gohrke S, Nickels S, Brauch H; GENICA Network, Ko YD, Fischer HP, Schmutzler RK, Meindl A, Bartram CR, Schott S, Engel C, Godwin AK, Weaver J, Pathak HB, Sharma P, Brenner H, Müller H, Arndt V, Stegmaier C, Miron P, Yannoukakos D, Stavropoulou A, Fountzilas G, Gogas HJ, Swann R, Dwek M, Perkins A, Milne RL, Benítez J, Zamora MP, Pérez JI, Bojesen SE, Nielsen SF, Nordestgaard BG, Flyger H, Guénel P, Truong T, Menegaux F, Cordina-Duverger E, Burwinkel B, Marmé F, Schneeweiss A, Sohn C, Sawyer E, Tomlinson I, Kerin MJ, Peto J, Johnson N, Fletcher O, Dos Santos Silva I, Fasching PA, Beckmann MW, Hartmann A, Ekici AB, Lophatananon A, Muir K, Puttawibul P, Wiangnon S, Schmidt MK, Broeks A, Braaf LM, Rosenberg EH, Hopper JL, Apicella C, Park DJ, Southey MC, Swerdlow AJ, Ashworth A, Orr N, Schoemaker MJ, Anton-Culver H, Ziogas A, Bernstein L, Dur CC, Shen CY, Yu JC, Hsu HM, Hsiung CN, Hamann U, Dünnebier T, Rüdiger T, Ulmer HU, Pharoah PP, Dunning AM, Humphreys MK, Wang Q, Cox A, Cross SS, Reed MW, Hall P, Czene K, Ambrosone CB, Ademuyiwa F, Hwang H, Eccles DM, Garcia-Closas M, Figueroa JD, Sherman ME, Lissowska J, Devilee P, Seynaeve C, Tollenaar RA, Hooning MJ, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Grip M, John EM, Miron A, Alnæs GG, Kristensen V, Børresen-Dale AL, Giles GG, Baglietto L, McLean CA, Severi G, Kosel ML, Pankratz VS, Slager S, Olson JE, Radice P, Peterlongo P, Manoukian S, Barile M, Lambrechts D, Hatse S, Dieudonne AS, Christiaens MR, Chenevix-Trench G; kConFab Investigators; AOCS Group, Beesley J, Chen X, Mannermaa A, Kosma VM, Hartikainen JM, Soini Y, Easton DF, Couch FJ. 19p13.1 is a triple-negative-specific breast cancer susceptibility locus. Cancer Res. 2012 Apr 1;72(7):1795-803. doi: 10.1158/0008-5472.CAN-11-3364. Epub 2012 Feb 13.
- Trump DL, Chadha MK, Sunga AY, Fakih MG, Ashraf U, Silliman CG, Hollis BW, Nesline MK, Tian L, Tan W, Johnson CS.Vitamin D deficiency and insufficiency among patients with prostate cancer.BJU Int. 2009 Oct;104(7):909-14. PMCID: PMC2889216
- Yao S, Sucheston LE, Smiley SL, Davis W, Conroy JM, Nowak NJ, Ambrosone CB, McCarthy PL Jr, Hahn T.Common genetic variants are associated with accelerated bone mineral density loss after hematopoietic cell transplantation.PLoS One. 2011;6(10):e25940. PMCID: PMC3195081
- Yao S, Sucheston LE, Millen AE, Johnson CS, Trump DL, Nesline MK, Davis W, Hong CC, McCann SE, Hwang H, Kulkarni S, Edge SB, O'Connor TL, Ambrosone CB.Pretreatment serum concentrations of 25-hydroxyvitamin D and breast cancer prognostic characteristics: a case-control and a case-series study.PLoS One. 2011 Feb 28;6(2):e17251. PMCID: PMC3046139
- Zhao H, Shen J, Medico L, Wang D, Ambrosone CB, Liu S.A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer.PLoS One. 2010 Oct 29; 5(10):e13735. PMCID: PMC2966402
- Zhao H, Shen J, Medico L, Platek M, Ambrosone CB.Length heteroplasmies in human mitochondrial DNA control regions and breast cancer risk.Int J Mol Epidemiol Genet. 2010 Apr 5;1(3):184-92. PMCID: PMC3076767
- Zheng YL, Ambrosone C, Byrne C, Davis W, Nesline M, McCann SE.Telomere length in blood cells and breast cancer risk: investigations in two case-control studies.Breast Cancer Res Treat. 2010 Apr; 120(3):769-75. PMID: 19543829